We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Ventas
VTR
$47.5B
| $15.5M | 0.04% |
422,100
-7,600
| -2% | -$251K |
|
452
Tyler Technologies
TYL
$12.6B
| $15.4M | 0.04% |
+44,400
| New | +$14.9M |
|
|
GTM
453
ZoomInfo Technologies
GTM
$1.08B
| $15.3M | 0.04% |
+300,000
| New | +$14.3M |
|
454
DraftKings
DKNG
$10.8B
| $15.3M | 0.04% |
+460,000
| New | +$12.7M |
|
455
International Flavors & Fragrances
IFF
$22.5B
| $15.2M | 0.04% |
123,896
-124,200
| -50% | -$15.7M |
|
456
Hormel Foods
HRL
$13.9B
| $15.2M | 0.04% |
314,146
+5,200
| +2% | +$248K |
|
|
HEES
457
DELISTED
H&E Equipment Services
HEES
| $15.1M | 0.04% |
819,504
-392,356
| -32% | -$6.24M |
|
458
EOG Resources
EOG
$71.5B
| $15.1M | 0.04% |
298,900
-1,168,900
| -80% | -$56.6M |
|
|
TIF
459
DELISTED
Tiffany & Co.
TIF
| $15M | 0.04% |
123,254
-719
| -0.6% | -$90K |
|
460
Biogen
BIIB
$30.5B
| $14.9M | 0.04% |
55,590
-150,300
| -73% | -$45.2M |
|
461
FMC
FMC
$1.35B
| $14.7M | 0.04% |
+147,700
| New | +$13.6M |
|
|
DRE
462
DELISTED
Duke Realty Corp.
DRE
| $14.6M | 0.04% |
413,700
-6,900
| -2% | -$235K |
|
|
BHVN
463
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $14.6M | 0.04% |
200,000
+3,025
| +2% | +$161K |
|
464
Enovis
ENOV
$1.74B
| $14.6M | 0.04% |
304,109
+15,699
| +5% | +$693K |
|
465
LKQ Corp
LKQ
$6.1B
| $14.6M | 0.04% |
556,690
+204,190
| +58% | +$5.02M |
|
466
Alibaba
BABA
$308B
| $14.6M | 0.04% |
67,500
-72,500
| -52% | -$15.1M |
|
|
NARI
467
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $14.5M | 0.04% |
+300,000
| New | +$14.3M |
|
468
MDU Resources
MDU
$4.18B
| $14.4M | 0.04% |
+1,709,425
| New | +$14.2M |
|
469
Rockwell Automation
ROK
$50.1B
| $14.3M | 0.04% |
+67,195
| New | +$13M |
|
470
Nucor
NUE
$62.6B
| $14.1M | 0.04% |
339,735
-5,800
| -2% | -$234K |
|
471
Shift4
FOUR
$4.23B
| $14M | 0.04% |
+393,632
| New | +$14.4M |
|
472
Vistra
VST
$47.4B
| $14M | 0.04% |
+750,000
| New | +$14.1M |
|
473
MacroGenics
MGNX
$248M
| $14M | 0.04% |
+500,000
| New | +$8.69M |
|
474
Northern Trust
NTRS
$33.7B
| $13.9M | 0.04% |
175,300
+41,400
| +31% | +$3.28M |
|
475
Avantor
AVTR
$9.04B
| $13.6M | 0.03% |
800,000
+100,000
| +14% | +$1.63M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.